article thumbnail

Could Higher Doses of Buprenorphine Help People With OUD Stay in Treatment?

Drug Topics

Treatment with buprenorphine has more than doubled since 2009, but dosing guidelines are based on studies with people using heroin that were done before the fentanyl crisis.

503
503
article thumbnail

2022-2023 Influenza Season Classified as High Severity by CDC

Drug Topics

This season marks the fourth to be classified as high severity since the 2009 influenza A(H1N1) pandemic.

469
469
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Iloperidone for Acute Treatment of Manic, Mixed Episodes in Bipolar I

Drug Topics

The drug was previously approved in 2009 to treat schizophrenia.

FDA 387
article thumbnail

STAT+: Two of FDA’s top cancer regulators to depart, heightening worries about drug reviews

STAT

Theoret, who joined as a medical reviewer in 2009, have told colleagues of plans to leave the FDA, multiple sources familiar with the matter told STAT. Both Paul G. Kluetz, who joined the FDA as a medical reviewer in 2016, and Marc R.

FDA 141
article thumbnail

Impact of IFM 2009 and DETERMINATION Studies

Pharmacy Times

Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients. (..)

65
article thumbnail

Between hope and despair: Improving cancer outcomes

PhRMA

In 2009, there weren’t many treatment options available, and the doctors weren’t sure how to respond because not many Black patients had had similar diagnoses, so there was little information to go forward on. Unfortunately, the tumor was diagnosed late in progression and inoperable.

Hospitals 203
article thumbnail

Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case

STAT

South San Francisco biotech Genentech on Thursday announced that an internal review of misconduct allegations concerning a landmark 2009 paper co-authored by Marc Tessier-Lavigne, a former top executive at the company and Stanford University’s current president, did not find any evidence of fraud or intentional wrongdoing.